CEO Natalie Holles describes how learnings from a setback from the company's first asset have resulted in a new program.

Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations.

He describes what made him excited about the company, and why he views diabetic retinopathy as potentially a bigger opportunity than wet AMD

Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.

Craig Tooman describes Silence's two lead programs targeting Lp(a) and polycythemia vera, as well as the company's broader platform.

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies.

Carolyn Bertozzi introduces Firefly and explains the idea behind combining the science of antibody-drug conjugates with protein degraders

Arnon Rosenthal walks us through the idea of the immune system playing a central role in neuro-degeneration

Jason Lettmann describes how he believes having an inactive Fc domain makes all the difference in the CD47 space.

Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.

Prime Medicine CEO Keith Gottesdiener describes the advantages he sees in prime editing.

Noland Townsend describes the science behind Lexeo's lead programs.

Amit Etkin describes Alto's approach to tyring to bring precision medicine to psychiatry.

Arrowhead CEO Chris Anzalone discusses the present and future of RNAi, and speaks on the company’s cardiometabolic and pulmonary programs.

Sumant Ramachandra describes why ImmPACT's programs target more than one antigen and the case for CD19/CD20 in oncology and autoimmune.

Jacob Berlin walks on the process that has allowed Terray to do well over 2 billion target / ligand binding measurements over 18 months.

Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing

Jeremy Levin walks us through the science of Ovid's CNS-focused pipeline, gives his take on the health of the biotech.

Matt Gline reflects on learnings from the Telavant success, and why he thinks Immunovant's FcRn might be best in class.

Herriot Tabuteau on his company's recent launches, submissions migraine and fibromyalgia, key data in narcolepsy and Alzheimer's, and more.